Next |
home / stock / oncy / oncy message board
Subject | By | Source | When |
---|---|---|---|
Next stop $3.00 then $4.00 then its pretty | accipiterr | investorshub | 06/22/2023 3:45:38 PM |
Also Phase 1 Clinical trials for viral loaded | accipiterr | investorshub | 06/22/2023 3:24:46 PM |
$ONCY IS A PHASE 3 BIOTECH COMPANY WITH | accipiterr | investorshub | 06/22/2023 3:20:16 PM |
I am here. Here is a comment for | accipiterr | investorshub | 06/22/2023 3:08:51 PM |
NEWS -- Oncolytics Biotech's® Pelareorep Selected for Inclusion | Paulness | investorshub | 06/22/2023 1:39:57 PM |
$ONCY got some short data | Paulness | investorshub | 06/19/2023 12:28:06 AM |
$ONCY should we be shorting? | Selain7 | investorshub | 06/16/2023 10:48:24 PM |
$ONCY Anyone hear anything lately? Want to see this one go | Cobra Stock Sleuth | investorshub | 06/16/2023 2:49:59 AM |
$ONCY and the shorts continue | Paulness | investorshub | 06/15/2023 2:51:57 AM |
Bristol-Myers Squibb news coming !!!!!!!!!!!!!!! | Paulness | investorshub | 06/06/2023 12:41:58 AM |
NEWS -- Oncolytics Biotech Announces Updated Randomized Phase | Paulness | investorshub | 06/05/2023 12:55:31 PM |
what does this mean? | Paulness | investorshub | 06/04/2023 10:08:02 PM |
When is this gonna take off? | Paulness | investorshub | 06/04/2023 4:47:39 PM |
$ONCY what do you make of this data? | Paulness | investorshub | 06/04/2023 6:57:52 AM |
$ONCY and the shorts continue | Paulness | investorshub | 06/02/2023 11:42:19 PM |
what do you make of this data? | KngmAz | investorshub | 06/01/2023 7:37:14 PM |
The trading | tknuncle | investorshub | 05/31/2023 8:05:46 PM |
$ONCY MomentumIts trading | Paulness | investorshub | 05/31/2023 1:29:48 PM |
great news | Cobra Stock Sleuth | investorshub | 05/31/2023 8:34:33 AM |
$ONCY short squeeze signal | 1984ISHERE | investorshub | 05/28/2023 12:02:50 AM |
News, Short Squeeze, Breakout and More Instantly...
Oncolytics Biotech Inc. Company Name:
ONCY Stock Symbol:
NASDAQ Market:
Oncolytics Biotech Inc. Website:
Oncolytics Biotech® Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial Canada NewsWire Anticipated evaluation to include combination therapy featuring treatment regimen of checkpoint inhibition and chemotherapy...
Oncolytics Biotech® Reports First Quarter 2024 Financial Results and Operational Highlights Canada NewsWire Pelareorep advancing to registration-enabling studies Preparations underway for Type C meeting with the FDA to establish registrational pathway in HR+/HER2-...
Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer Canada NewsWire US$5 million PanCAN grant provides important support for the fifth cohort of the GOBLET st...